SpringWorks Therapeutics Newsroom

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)

TipRanksDec 24 06:25 ET

Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63

Moomoo NewsDec 24 05:34 ET

J.P. Morgan Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)

TipRanksNov 21 07:08 ET

SpringWorks Therapeutics Initiated at Outperform by Evercore ISI Group

Dow JonesNov 20 12:11 ET

SpringWorks Therapeutics Analyst Ratings

BenzingaNov 20 12:01 ET

Evercore Initiates SpringWorks Therapeutics(SWTX.US) With Buy Rating, Announces Target Price $60

Moomoo NewsNov 20 08:33 ET

A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $58 to $74

Moomoo NewsNov 13 08:06 ET

Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)

TipRanksNov 13 05:21 ET

Buy Rating Reaffirmed for Springworks Therapeutics Amid Promising Outlook for Ogsiveo and Mirdametinib

TipRanksNov 13 05:08 ET

SpringWorks Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 12 11:27 ET

Springworks Therapeutics: Strong Cash Position and Promising Drug Approval Outlook Justify Buy Rating

TipRanksNov 12 10:48 ET

TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63

Moomoo NewsOct 21 07:31 ET

TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)

TipRanksOct 21 06:55 ET

SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan

Dow JonesSep 4 18:12 ET

J.P. Morgan Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Raises Target Price to $68

Moomoo NewsSep 4 07:33 ET

Goldman Sachs Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating

Moomoo NewsSep 3 00:31 ET

SpringWorks Therapeutics Analyst Ratings

BenzingaAug 28 10:18 ET

H.C. Wainwright Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $76

Moomoo NewsAug 28 09:31 ET

Wedbush Raises Price Target on SpringWorks Therapeutics to $77 From $75, Maintains Outperform Rating

MT NewswiresAug 28 09:09 ET

Buy Rating Affirmed for Springworks Therapeutics on Strong Outlook for Mirdametinib

TipRanksAug 28 08:37 ET